# OnCo record aml-older-unfit (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml-older-unfit/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml-older-unfit" ;
  schema:name "Acute myeloid leukaemia in older or unfit patients"@en ;
  schema:alternateName "Unfit AML"@en, "AML in the elderly"@en, "AML ineligible for intensive chemotherapy"@en, "Low-intensity AML therapy"@en ;
  schema:description "Most people with acute myeloid leukaemia are over 65, and many cannot take intensive chemotherapy. Venetoclax with azacitidine, two gentler drugs, doubled remission rates and lengthened life in this group, replacing the old choice between supportive care and low-dose chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/aml-older-unfit/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_myeloid_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/geriatric-assessment/>, <https://onco.cc/technologies/g8-geriatric-screening/> ;
  onco:targets <https://onco.cc/targets/bcl2/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/hma/>, <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/terms/eln-risk/> ;
  onco:pipeline <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/ideas/idea-shortened-venetoclax/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/technologies/g8-geriatric-screening/>, <https://onco.cc/technologies/geriatric-assessment/> ;
  onco:standardOfCare <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/decitabine/>, <https://onco.cc/trials/viale-a/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/trials/agile/>, <https://onco.cc/pairings/venetoclax-plus-hma/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/drugs/cpx-351/>, <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/drugs/glasdegib/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/technologies/allogeneic-hsct/> .